[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

YU48594B - Organske soli n-n'-diacetilcistina i postupak njihovog dobijanja - Google Patents

Organske soli n-n'-diacetilcistina i postupak njihovog dobijanja

Info

Publication number
YU48594B
YU48594B YU99092A YU99092A YU48594B YU 48594 B YU48594 B YU 48594B YU 99092 A YU99092 A YU 99092A YU 99092 A YU99092 A YU 99092A YU 48594 B YU48594 B YU 48594B
Authority
YU
Yugoslavia
Prior art keywords
diacetylcystine
preparation
organic salts
forms
dinac
Prior art date
Application number
YU99092A
Other languages
English (en)
Other versions
YU99092A (sh
Inventor
Carl-Magnus Andersson
Hakan Bergstrand
Edib Jakupovic
Bo-Goran Josefsson
Magnus Lindvall
Bengt Sarnstrand
Eric Teneberg
Original Assignee
Aktiebolaget Astra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aktiebolaget Astra filed Critical Aktiebolaget Astra
Publication of YU99092A publication Critical patent/YU99092A/sh
Publication of YU48594B publication Critical patent/YU48594B/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/22—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of hydropolysulfides or polysulfides
    • C07C319/24—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of hydropolysulfides or polysulfides by reactions involving the formation of sulfur-to-sulfur bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

So organske baze i N,N'-diacetil-cistina u obliku njegovih pojedinačnih izomera, tj. kao D-, L- i mezo-oblici, kao i njegovi racemski oblici (DiNAc), naznačena time, što ima opštu formulu: gde je R+ i R2+ katjon organske baze, izabran iz grupe koju čine lizin, etilendiamin, N,N'-dibenziletilendiamin, adamantanamin, N-benzil-2-feniletilamin ili piperazin. -Prijava sadrži još 1 nezavisan i 2 zavisna zahteva.
YU99092A 1991-11-29 1992-11-18 Organske soli n-n'-diacetilcistina i postupak njihovog dobijanja YU48594B (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9103572A SE9103572D0 (sv) 1991-11-29 1991-11-29 Organic salts of n,n'-diacetyl cystine

Publications (2)

Publication Number Publication Date
YU99092A YU99092A (sh) 1995-12-04
YU48594B true YU48594B (sh) 1998-12-23

Family

ID=20384494

Family Applications (1)

Application Number Title Priority Date Filing Date
YU99092A YU48594B (sh) 1991-11-29 1992-11-18 Organske soli n-n'-diacetilcistina i postupak njihovog dobijanja

Country Status (38)

Country Link
US (5) US5385904A (sh)
EP (1) EP0621862B1 (sh)
JP (1) JP3302018B2 (sh)
KR (1) KR100256185B1 (sh)
CN (1) CN1039586C (sh)
AP (1) AP350A (sh)
AT (1) ATE141913T1 (sh)
AU (1) AU657827B2 (sh)
CA (1) CA2123516A1 (sh)
CZ (1) CZ282085B6 (sh)
DE (1) DE69213256T2 (sh)
DK (1) DK0621862T3 (sh)
DZ (1) DZ1637A1 (sh)
EE (1) EE03025B1 (sh)
ES (1) ES2090713T3 (sh)
FI (1) FI942504A (sh)
GR (1) GR3021546T3 (sh)
HK (1) HK62297A (sh)
HR (1) HRP921322B1 (sh)
HU (1) HU215390B (sh)
IL (1) IL103778A (sh)
IS (1) IS1645B (sh)
LV (1) LV11949B (sh)
MA (1) MA22716A1 (sh)
MX (1) MX9206851A (sh)
MY (1) MY110523A (sh)
NO (1) NO301325B1 (sh)
NZ (1) NZ245077A (sh)
PL (2) PL171336B1 (sh)
RU (1) RU2135468C1 (sh)
SE (1) SE9103572D0 (sh)
SG (1) SG73962A1 (sh)
SI (1) SI9200351A (sh)
SK (1) SK281697B6 (sh)
TN (1) TNSN92108A1 (sh)
WO (1) WO1993011104A1 (sh)
YU (1) YU48594B (sh)
ZA (1) ZA928739B (sh)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865463A (en) * 1973-11-12 1975-02-11 Busch & Co Inc Ag Electrical adapter plug
EP0494405B2 (en) * 1991-01-10 2000-04-19 Transcend Therapeutics, Inc. Use of L-2-oxo thiazolidine-4-carboxylate for the treatment of pulmonary diseases
US5747459A (en) * 1991-02-04 1998-05-05 Nestec, Ltd. Method for insuring adequate intracellular glutathione in tissue
US5430045A (en) * 1992-04-23 1995-07-04 Free Radical Sciences, Inc. Method of reducing or preventing bone marrow hypoplasia
US5447712A (en) * 1993-12-09 1995-09-05 Free Radical Sciences Method of reducing cyclophosphamide induced hemorrhagic cystitis
SE9500897D0 (sv) * 1995-03-14 1995-03-14 Astra Ab The pharmacological use of certain cystine derivatives
SE9602262D0 (sv) * 1996-06-06 1996-06-06 Astra Ab New use of derivatives of cystine
US6017959A (en) * 1996-06-18 2000-01-25 Astra Aktiebolag Forms of organic salts of N,N'-diacetylcystine
SE9602416D0 (sv) * 1996-06-18 1996-06-18 Astra Ab New forms of an organic salt of N'N-diacetylcystine
AR007398A1 (es) * 1996-06-18 1999-10-27 Astrazeneca Ab Proceso para preparar sales inorganicas de n-n'-diacetilcistina
CN1059907C (zh) * 1997-05-23 2000-12-27 中国石油化工集团公司巴陵石化岳阳石油化工总厂 一种含共轭二烯轻聚合物的选择氢化方法
US20030203006A1 (en) * 1997-10-29 2003-10-30 Ajinomoto Co. Inc. Immunomodulator
US6197749B1 (en) * 1997-10-29 2001-03-06 Ajinomoto Co., Inc. Method of suppressing immune responses by reducing intracellular content of glutathione in macrophages and monocytes
SE9800932D0 (sv) 1998-03-20 1998-03-20 Astra Ab New compunds
EP1004302A3 (en) * 1998-10-29 2003-06-04 Ajinomoto Co., Inc. Immunomodulator
SE9900438D0 (sv) * 1999-02-10 1999-02-10 Astra Ab The pharmacological use of certian cystine derivatives
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
SE518784C2 (sv) * 2000-12-27 2002-11-19 Nactilus Ab "N-Acetyl-L-cystein med kompositioner för behandling av neoplasier"
EP1374831A4 (en) * 2001-03-13 2007-07-11 Ajinomoto Kk COSMETICS OR TOPICAL SKIN PREPARATIONS
CA2479751C (en) 2002-03-20 2008-06-03 Trent Poole Inhalation apparatus
DE602005024413D1 (de) 2004-08-20 2010-12-09 Mannkind Corp Katalyse der diketopiperazinsynthese
EP2314298B1 (en) 2004-08-23 2015-05-27 MannKind Corporation Microparticles comprising diketopiperazine salts for drug delivery
RU2390325C2 (ru) 2005-09-14 2010-05-27 Маннкайнд Корпорейшн Способ приготовления лекарственного препарата, основанный на увеличении сродства активных агентов к поверхностям кристаллических микрочастиц
WO2007098500A2 (en) 2006-02-22 2007-08-30 Mannkind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US8438729B2 (en) * 2006-03-09 2013-05-14 Canon Kabushiki Kaisha Method of producing liquid discharge head
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CN101827626B (zh) 2008-06-13 2015-03-18 曼金德公司 干粉吸入器和用于药物输送的系统
JP5479465B2 (ja) * 2008-06-20 2014-04-23 マンカインド コーポレイション 吸入努力をリアルタイムにプロファイルする対話式機器および方法
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2676695A3 (en) 2009-03-11 2017-03-01 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
US8734845B2 (en) 2009-06-12 2014-05-27 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
BR112012033060A2 (pt) 2010-06-21 2018-02-27 Mannkind Corp métodos de sistema de liberação de fármaco em pó seco
SG194034A1 (en) 2011-04-01 2013-11-29 Mannkind Corp Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
AU2012328885B2 (en) 2011-10-24 2017-08-31 Mannkind Corporation Methods and compositions for treating pain
CN102491926B (zh) * 2011-12-15 2013-09-25 青岛市药品检验所 一种硫普罗宁二硫化物的制备和纯化方法
BR112015000529B1 (pt) 2012-07-12 2022-01-11 Mannkind Corporation Inalador de pó seco
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
KR102499439B1 (ko) 2013-03-15 2023-02-13 맨카인드 코포레이션 미세결정성 디케토피페라진 조성물 및 방법
MX2020009878A (es) 2013-07-18 2022-07-27 Mannkind Corp Composiciones farmaceuticas en polvo seco estables al calor y metodos.
JP2016530930A (ja) 2013-08-05 2016-10-06 マンカインド コーポレイション 通気装置及び方法
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
WO2021219376A1 (en) * 2020-04-28 2021-11-04 Unilever Ip Holdings B.V. Personal care compositions with enhanced solubility actives
US20230372272A1 (en) * 2020-09-28 2023-11-23 Georgia Tech Research Corporation Use of cystine and derivatives thereof as anti-thrombotic and thrombolytic agents

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB592631A (en) * 1945-04-04 1947-09-24 Du Pont Cysteine and cystine
GB954268A (en) 1962-02-26 1964-04-02 Mead Johnson & Co Decongestant compositions comprising n-acylated sulphydryl compounds
FR8205M (sh) * 1968-12-20 1970-09-14
US3647834A (en) * 1969-08-11 1972-03-07 Mead Johnson & Co Zinc mercaptide n-acetylcysteine carboxylate salts
US3878305A (en) * 1972-05-25 1975-04-15 Procter & Gamble Fortification of foodstuffs with n-acyl derivatives of sulphur-containing l-amino acids
US3952115A (en) * 1975-04-02 1976-04-20 The Procter & Gamble Company Fortification of foodstuffs with N-acyl derivatives of sulfur-containing L-amino acid esters
US4141734A (en) * 1975-09-11 1979-02-27 Ciba-Geiby Ag Photographic developing process
US4093739A (en) * 1977-06-15 1978-06-06 Mead Johnson & Company Mercaptoacylamidobenzoyl glycine and mucolytic process
JPS6011888B2 (ja) * 1978-10-11 1985-03-28 参天製薬株式会社 リウマチ疾患治療薬
JPS56155298A (en) * 1980-05-02 1981-12-01 Tanabe Seiyaku Co Shampoo composition
FR2503151A1 (fr) * 1981-04-02 1982-10-08 Morelle Jean Butyryminoacides soufres. mode de preparation. emploi comme element keratogenique chez l'homme et l'animal et comme agent de fertilisation chez les vegetaux
GB2097256B (en) * 1981-04-02 1985-05-30 Morelle Jean V Compositions containing n-butyryl alphaaminoacids
JPS58164566A (ja) * 1982-03-09 1983-09-29 Kenji Okawa シスチン類の製造法
US4724239A (en) * 1985-09-16 1988-02-09 Morgan Lee R Method of treating chemical ulcers with N,N'-diacetylcystine, N-acetyl homocysteine and N-acetyl cysteine
US4827016A (en) * 1985-09-16 1989-05-02 Morgan Lee R Method and compounds for reducing dermal inflammations
US4708965A (en) * 1985-09-16 1987-11-24 Morgan Lee R Method of treating herpes virus infections with N,N'-diacetylcystine and derivatives
JPH0660157B2 (ja) * 1985-11-20 1994-08-10 三井東圧化学株式会社 システインからシスチンを製造する方法
JPS62195356A (ja) * 1986-02-20 1987-08-28 Seiwa Kasei:Kk シスチン誘導体及びその塩
AT402931B (de) * 1986-11-07 1997-09-25 Pharmacia Gmbh Verfahren zur herstellung von neuen cystinverbindungen und derenverwendung
SE8704542D0 (sv) * 1987-11-19 1987-11-19 Draco Ab New derivatives of cysteine
IL98310A (en) * 1990-06-08 1996-08-04 Astra Ab Medicinal preparations containing a history of cystine
TW221376B (sh) * 1990-06-28 1994-03-01 Astra Ab
GB9111885D0 (en) * 1991-06-03 1991-07-24 Erba Carlo Spa Nerve growth factor for use in the prevention and treatment of viral infections

Also Published As

Publication number Publication date
AU3099692A (en) 1993-06-28
ES2090713T3 (es) 1996-10-16
FI942504A0 (fi) 1994-05-27
DE69213256D1 (de) 1996-10-02
DK0621862T3 (da) 1996-09-16
HUT70851A (en) 1995-11-28
SE9103572D0 (sv) 1991-11-29
HU9401473D0 (en) 1994-08-29
RU2135468C1 (ru) 1999-08-27
JP3302018B2 (ja) 2002-07-15
DZ1637A1 (fr) 2002-02-17
IS1645B (is) 1997-03-25
SI9200351A (en) 1993-06-30
TNSN92108A1 (fr) 1993-06-08
IL103778A (en) 1997-08-14
SK281697B6 (sk) 2001-06-11
PL171336B1 (en) 1997-04-30
US5650538A (en) 1997-07-22
NO941968L (no) 1994-05-26
IS3949A (is) 1993-05-30
SG73962A1 (en) 2000-07-18
ZA928739B (en) 1993-06-09
KR100256185B1 (ko) 2000-05-15
WO1993011104A1 (en) 1993-06-10
HU215390B (hu) 1998-12-28
CN1073683A (zh) 1993-06-30
MX9206851A (es) 1993-05-01
US5804582A (en) 1998-09-08
PL170787B1 (en) 1997-01-31
DE69213256T2 (de) 1997-01-23
ATE141913T1 (de) 1996-09-15
JPH07501539A (ja) 1995-02-16
CN1039586C (zh) 1998-08-26
US5693858A (en) 1997-12-02
CZ129794A3 (en) 1995-01-18
CZ282085B6 (cs) 1997-05-14
NZ245077A (en) 1995-04-27
SK63294A3 (en) 1995-02-08
MA22716A1 (fr) 1993-07-01
IL103778A0 (en) 1993-04-04
NO301325B1 (no) 1997-10-13
YU99092A (sh) 1995-12-04
HRP921322A2 (en) 1996-10-31
GR3021546T3 (en) 1997-02-28
EP0621862B1 (en) 1996-08-28
AP350A (en) 1994-08-09
US5824681A (en) 1998-10-20
AP9200448A0 (en) 1993-01-31
LV11949B (en) 1998-07-20
LV11949A (lv) 1998-01-20
HK62297A (en) 1997-05-16
NO941968D0 (no) 1994-05-26
EP0621862A1 (en) 1994-11-02
AU657827B2 (en) 1995-03-23
HRP921322B1 (en) 1998-12-31
EE03025B1 (et) 1997-08-15
FI942504A (fi) 1994-05-27
US5385904A (en) 1995-01-31
MY110523A (en) 1998-07-31
CA2123516A1 (en) 1993-06-10

Similar Documents

Publication Publication Date Title
YU48594B (sh) Organske soli n-n'-diacetilcistina i postupak njihovog dobijanja
DK0714300T3 (da) Fremgangsmåder til regulering af den seksuelle reaktion hos mennesker
FI961809A0 (fi) Uudet (R)-5-karbamoyyli-8-fluori-3-N,N-disubstituoitu-amino 3,4-dihydro-2H-1-bentsopyraanit
ATE254443T1 (de) Inhibitierung des haarwuchses
AR013441A1 (es) Un compuesto de imidazoquinoxalina, metodo para el tratamiento de un padecimiento o desorden asociado con la proteina tirosinaquinasa, lascomposiciones farmaceuticas que las contienen y metodos para preparar dichos compuestos y sus intermediarios
UY25242A1 (es) Inhibidores de benzotiazol de la proteína tirosina cinasa
YU49094B (sh) Postupak za dobijanje sinergističke terapeutske kompozicije
EA200300248A1 (ru) Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
DK0526488T3 (da) Benzylphosphonsyre-tyrosinkinaseinhibitorer
SE9504661D0 (sv) New compounds
DE69115280D1 (de) Indolderivate, die die leukotrienbiosynthese hemmen.
EA200200510A1 (ru) 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр
ES8802420A1 (es) Un procedimiento para la preparacion de un derivado de acido 5-imidazolcarboxilico
UA26431A (uk) Похідhі сиh-ізомеру цефалоспориhу, їх оптичhо активhі аhтиподи або рацемічhа суміш, а також їх фармацевтичhо прийhятhі кислотhо-адитивhі солі
ES2117976T3 (es) Preparacion de derivados n-acetil neuraminicos.
GB1426028A (en) 2-oxazoline derivatives
DK0775158T3 (da) Cyclopeptolider
YU48671B (sh) Novi derivati beta-fenilizoserina, njegovo dobijanje i primena
EP1008349A4 (en) PROMOTORS OF NEOVASCULARIZATION
DE69118204D1 (de) Bekämpfung von parasitischen nematoden
ATE227122T1 (de) Stabilisierte tablettenformulierung
ATE213742T1 (de) Zyklische somatostatinanaloge mit wachstumhormon inhibierender aktivität
BG90414A (bg) 2-азабицикло (2,2,1)-хепт-5- ен-2-оцетна киселина и нейни производни, метод за получаване и приложението им
NO990159D0 (no) FremgangsmÕte for fremstilling av enantiomerisk anrikede N-acylazetidin-2-karboksylsyrer
MX9207543A (es) Sales estables de acido (+)-(1s,2r)-[[b.(2-hidroxilamino-2-oxoetil)-n-metilamino]carbonil]cicl ohexan-1-carboxilico, procedimiento para su preparacion, y composiciones farmaceuticas que las contienen